<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070213</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000330142</org_study_id>
    <secondary_id>NCRI-FOCUS2</secondary_id>
    <secondary_id>MRC-CR09</secondary_id>
    <secondary_id>EU-20303</secondary_id>
    <nct_id>NCT00070213</nct_id>
  </id_info>
  <brief_title>Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, capecitabine, and&#xD;
      oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining more than one drug may kill more tumor cells. It is not yet known whether&#xD;
      leucovorin and fluorouracil with or without oxaliplatin is more effective than capecitabine&#xD;
      with or without oxaliplatin in treating patients who have metastatic colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying four different chemotherapy regimens to&#xD;
      compare how well they work in treating patients with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the progression-free survival of patients with metastatic colorectal&#xD;
           adenocarcinoma treated with leucovorin calcium and fluorouracil with vs without&#xD;
           oxaliplatin or capecitabine with vs without oxaliplatin.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these fluorouracil-based vs&#xD;
           capecitabine-based regimens.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the failure-free and overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxic effects and adverse events associated with these regimens in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the limited health assessments of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the health economics associated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 4 treatment&#xD;
      arms and receive 12 weeks of therapy.&#xD;
&#xD;
        -  Arm I (MdG regimen): Patients receive leucovorin calcium IV over 2 hours on day 1 and&#xD;
           fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 14 days for up&#xD;
           to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with disease progression during or within 8 weeks of the completion of this regimen&#xD;
      may cross over and receive second-line therapy on arm II.&#xD;
&#xD;
        -  Arm II (OxMdG regimen): Patients receive leucovorin calcium IV over 2 hours and&#xD;
           oxaliplatin IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day&#xD;
           1. Treatment repeats every 14 days for up to 6 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with disease progression during or within 8 weeks of the completion of this regimen&#xD;
      may receive second-line therapy or supportive care off-study.&#xD;
&#xD;
        -  Arm III (Cap regimen): Patients receive oral capecitabine twice daily on days 1-15.&#xD;
           Treatment repeats every 21 days for up to 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with disease progression during or within 8 weeks of the completion of this regimen&#xD;
      may cross over and receive second-line therapy on arm IV.&#xD;
&#xD;
        -  Arm IV (OxCap regimen): Patients receive oxaliplatin IV over 2 hours on day 1 and oral&#xD;
           capecitabine twice daily on days 1-15. Treatment repeats every 21 days for up to 4&#xD;
           courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with disease progression during or within 8 weeks of the completion of this regimen&#xD;
      may receive second-line therapy or supportive care off-study.&#xD;
&#xD;
      All patients are then re-evaluated at least every 6 weeks and begin another 12 weeks of&#xD;
      therapy at any evidence (e.g., clinical, radiological, or tumor marker) of disease&#xD;
      progression. Patients with chemo-sensitive disease may repeat alternating 12-week therapy&#xD;
      sessions and evaluation periods indefinitely.&#xD;
&#xD;
      Quality of life is assessed at baseline, at 12-14 weeks, at 24 weeks, and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 460 patients (115 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 1, 2011</completion_date>
  <primary_completion_date type="Actual">June 1, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Compare progression-free survival (PFS) in pts. treated w/ leucovorin calcium + fluorouracil (MdG) vs leucovorin calcium + fluorouracil + oxaliplatin (OxMdG) and in pts. treated w/ capecitabine (Cap) vs capecitabine + oxaliplatin (OxCap) at 1 yr</measure>
    <time_frame>PFS</time_frame>
    <description>Compare progression-free survival (PFS) in pts. treated w/ leucovorin calcium + fluorouracil (MdG) vs leucovorin calcium + fluorouracil + oxaliplatin (OxMdG) and in pts. treated w/ capecitabine (Cap) vs capecitabine + oxaliplatin (OxCap) at 1 yr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks</measure>
    <time_frame>Baseline and 14 weeks</time_frame>
    <description>Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 14 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare health assessment, including quality of life, in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap at baseline and 14 and 24 weeks</measure>
    <time_frame>Baseline, 14 and 24 weeks</time_frame>
    <description>Compare health assessment, including quality of life, in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap at baseline and 14 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare toxicity/adverse events in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</measure>
    <time_frame>post 24 weeks</time_frame>
    <description>Compare toxicity/adverse events in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall failure-free survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</measure>
    <time_frame>post 24 weeks</time_frame>
    <description>Compare overall failure-free survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</measure>
    <time_frame>post 24 weeks</time_frame>
    <description>Compare overall survival in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare health economics in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</measure>
    <time_frame>Baseline, 14 and 24 weeks</time_frame>
    <description>Compare health economics in patients treated with MdG vs OxMdG and in patients treated with Cap vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare health assessment in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</measure>
    <time_frame>Baseline, 14 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare toxicity/adverse events in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 24 weeks</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Compare toxicity/adverse events in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap at baseline and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare patients acceptability in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</measure>
    <time_frame>post 24 weeks</time_frame>
    <description>Compare patients acceptability in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare PFS in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</measure>
    <time_frame>post 24 weeks</time_frame>
    <description>Compare PFS in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</measure>
    <time_frame>Baseline, 14 and 24 weeks</time_frame>
    <description>Compare health economics in patients treated with MdG vs Cap and in patients treated with OxMdG vs OxCap</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MdG (modified de Gramont)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weekly 5FU/FA schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MdG + oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OxCap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <arm_group_label>MdG (modified de Gramont)</arm_group_label>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>Capcitabine</arm_group_label>
    <arm_group_label>OxCap</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>MdG (modified de Gramont)</arm_group_label>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>MdG (modified de Gramont)</arm_group_label>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>OxCap</arm_group_label>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Capcitabine</arm_group_label>
    <arm_group_label>MdG (modified de Gramont)</arm_group_label>
    <arm_group_label>OxCap</arm_group_label>
    <arm_group_label>OxMdG (80%) for 12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of colorectal adenocarcinoma, defined by 1 of the following:&#xD;
&#xD;
               -  Prior or current histologically confirmed primary adenocarcinoma of the colon or&#xD;
                  rectum with clinical/radiological evidence of advanced/metastatic disease&#xD;
&#xD;
               -  Histologically or cytologically confirmed metastatic adenocarcinoma with&#xD;
                  clinical/radiological evidence of colorectal primary tumor&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
          -  Unfit and unsuitable for full-dose combination chemotherapy, which would include 1 of&#xD;
             the following circumstances:&#xD;
&#xD;
               -  Unsuitable or unwilling to be entered into any full-dose chemotherapy protocol&#xD;
&#xD;
               -  Ineligible or unsuitable for first-line standard combination as per National&#xD;
                  Institute of Clinical Excellence guidance&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min OR&#xD;
&#xD;
          -  Glomerular filtration rate greater than 30 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No recent myocardial infarction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No partial or complete bowel obstruction&#xD;
&#xD;
          -  No concurrent severe uncontrolled medical illness that would preclude study treatment&#xD;
&#xD;
          -  No psychiatric or neurological condition that would preclude giving informed consent&#xD;
             or complying with oral study medication&#xD;
&#xD;
          -  No other prior or concurrent malignant disease that would preclude study treatment or&#xD;
             assessment of response&#xD;
&#xD;
          -  No prior neuropathy greater than grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 months since prior adjuvant chemotherapy with fluorouracil with or without&#xD;
             leucovorin calcium&#xD;
&#xD;
          -  More than 1 month since prior rectal chemoradiotherapy with fluorouracil with or&#xD;
             without leucovorin calcium&#xD;
&#xD;
          -  No prior systemic palliative chemotherapy for metastatic disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent brivudine or sorivudine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew T. Seymour, MA, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cookridge Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gareth Griffiths</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Research Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials and Research Unit of the University of Leeds</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS2 9JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Council Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://events.cancer.gov/sites/default/files/assets/DCP-olderadultaccrual/Study%20Design%20and%20Assessment.pdf</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <results_reference>
    <citation>Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.</citation>
    <PMID>21570111</PMID>
  </results_reference>
  <results_reference>
    <citation>Seymour MT, Maughan TS, Wasan HS, et al.: Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-9030, 500s, 2007.</citation>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Cheryl Pugh</investigator_full_name>
    <investigator_title>Clinical Project manager for FOCUS2 for Sponsor</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

